2171 — CARsgen Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00- HK$6.66bn
- HK$5.18bn
- CNY125.66m
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer
China approves CARsgen's CAR-T treatment for stomach cancer (updated)
China approves CARsgen Therapeutics satricabtagene autoleucel 'satri-cel' injection
Brief: CARsgen Therapeutics Announces Placing Of Up To 23.7 Million Shares At HK$19.84 Per Share
CARsgen Therapeutics jumps most on record as full-year losses narrow
Brief: Carsgen Therapeutics Posts Group Revenue Of RMB125.7 Million For Year
Brief: Carsgen Therapeutics Announces 2025 Annual Results
Brief: CARsgen Therapeutics Entering Into Strategic Cooperation Agreements
Brief: Carsgen Therapeutics Sees FY Net Loss Of Up To RMB120 MLN
Brief: Carsgen Therapeutics Says Yijie Concert Group Purchased 335,000 Shares From November 6 To December 17
Brief: Carsgen Therapeutics Sees Net Loss Not More Than RMB80 Million In HY
Brief: Carsgen Therapeutics Says NMPA Accepted New Drug Application For Satricabtagene Autoleucel
CARsgen Therapeutics hits nearly 11-week high on share buyback plan
Brief: Carsgen Therapeutics To Repurchase Shares Not Exceeding 1% Of Total Issued Shares In Open Market
Brief: CARsgen Therapeutics Says Net Loss Was Around RMB798 Mln For Year
Brief: Carsgen Therapeutics Posts FY Net Income RMB -798 Mln